November 11, 2026 · Phase 2 readout
PGEN Phase 2 readout: a neutral outcome, +4.4%
On November 11, 2026, PRGN-2009 plus Pembrolizumab — Precigen, Inc. (Cervical Cancer) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved +4.4% in the window around the event. It had already run -41.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$4.52
1d before
$4.72
Event day
$4.66
1d after
$4.54
5d after
Our prediction vs. the result
CatalystAlert called this one up (+5.0% expected); the stock actually moved +4.4%. Model confidence at the time: 60%.
See the full scored track recordPre-catalyst setup
-41.6%
30-day run-up
12340%
30-day volatility
0.9×
volume spike
